# A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

> **NCT05585320** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immuneering Corporation** · enrollment: 209 (actual)

## Conditions studied

- Advanced Solid Tumor
- Pancreatic Adenocarcinoma
- Malignant Melanoma (Cutaneous)
- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** IMM-1-104 Monotherapy (Treatment Group A)
- **DRUG:** IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
- **DRUG:** IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- **DRUG:** IMM-1-104 + dabrafenib (Treatment Group D)
- **DRUG:** IMM-1-104 + pembrolizumab (Treatment Group E)

## Key facts

- **NCT ID:** NCT05585320
- **Lead sponsor:** Immuneering Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-31
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585320, "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05585320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*